

Product Managers Highlight Their Products



MATTHEW KOHLS

While recombinant IB4-SAP (rIB4-SAP, Cat. #IT-10) has traditionally been used to eliminate cell populations that display alpha-D-galactose on the cell membrane, such as non-peptidergic c-fiber nociceptor neurons, it has also been

found to be a very effective way to create stable transfected cell lines without the use of drug resistance genes. A recent publication by Sato *et al.* (*J Biotechnology* 10(1):143-153, 2015) demonstrates a new use for this conjugate.



LEONARDO ANCHETA

Looking for a new way to use our targeted toxins? Let ATS shed a little light on the subject. Researchers have used our targeted toxin technology in conjunction with photochemical internalization (PCI), a light-triggered technique that can help facilitate release of molecules from endocytic vesicles

once inside the cytosol. Researchers are using this method to overcome resistance that develops towards therapeutic agents or intracellular barriers encountered when introducing molecules into cancer cells. Berstad *et al.* (*Biochim Biophys Acta* 1820(12):1849-1858, 2012), Bostad *et al.* (*Mol Pharm* 11(8):2764-2776, 2014), and Berg *et al.* (*Methods Mol Biol* 635:133-145, 2010) demonstrate the use of this pairing with biotinylated antibodies combined with streptavidin-ZAP (Cat. #IT-27).



LUCAS CHANCE

No, he's not a Product Manager. . . yet!

Welcome to Lucas Ancheta (son to Leonardo and Kate Ancheta), born April 14, 2015, weighing in at 5 lb, 2 oz.



BRIAN RUSSELL

Opioid receptors are a group of inhibitory G protein-coupled receptors that are heavily involved in analgesia, respiratory depression, GI motility, and addiction. ATS has a comprehensive collection of products that help researchers illuminate the role of opioid receptors. Dermorphin-SAP (Cat. #IT-

12), Deltorphin-SAP (Cat. #BETA-006), Dynorphin-SAP (Cat. #IT-68), and Nociceptin-SAP (Cat. #BETA-001) have been shown to selectively eliminate cells expressing the mu (MOR), delta (DOR), kappa (KOR), or the ORL1 receptor, respectively. With these tools in hand, scientists have continued to discover new ways in which animals, and by extension, humans, respond to exogenous opioid therapy.



PATRICK SHRAMM

Cannabinoid receptors are involved in a variety of physiological responses including appetite, pain sensation, mood, and memory. We are now offering Anti-CB1-SAP (Cat. #BETA-005) to target and eliminate cells that express the CB1 receptor. Take advantage of this targeted toxin while it's still available as a beta

product. If you're the first to publish data* you'll receive a \$500 credit for use on ATS products.

**Data subject to review.*



CHELSEA FRIEDMAN

Chlorotoxin, a peptide from the venom of the deathstalker scorpion, has been shown to bind to matrix metalloproteinase-2 (MMP-2) isoforms. These isoforms are upregulated in gliomas and other cancers of neuroectodermal origin, but are not normally expressed in the brain.

Chlorotoxin-SAP (Cat. #BETA-010) is a bonded toxin between chlorotoxin and saporin, and can be a helpful tool in your research by allowing you to specifically target and eliminate cells expressing MMP-2 isoforms without affecting other cells.

Congratulations to the puzzle solvers from last quarter. Each winner will receive an ATS jigsaw puzzle.

**Solve this quarter's teaser at
www.ATSBio.com/news/15q3_teaser.html**

LAST QUARTER'S WINNERS: Glenn H. Kageyama, Cal Poly Pomona Univ * Dave Ginsberg, Molecular Innovations * Judene Bliss, Roswell Park Cancer Institute * Daniel Pekala, Charles River Laboratories * Joan Schein, Biochain * Seto Chice, SUNY HSC at Brooklyn * Bill Henry, Rhode Island Hospital

